

# Background information

## Venue

- Global Innovation Summit 2021, 18-19 November

## Time and place

- 18 November, 14:10- 14:55 (18:40-19:25 local time)

## Audience (~2000)

- Inauguration by Prime Minister of India
- Minister of health & Secretaries of central ministries
- Policy Makers , Industry Captains and Thought leaders

## Session

Special Address: Global Experience of Accelerating Innovation

- Professor Robert Langer, MIT (20 min)
- Martin Holst Lange, NN (20 min)

## Additional information

- Dry-run (logistics test) 15 min 16 or 17 November (LJPS)
- Information on organiser (IPA)
  - IPA is the apex policy association in India with 23 members contributing 57% of domestic sales , 85% of R&D expenditure and 80% exports from India
  - Health care is the key thrust area and there is significant realization that India should move up the value chain with the advantage of Global Scale in Manufacturing , Science and Technology Talent , Democratic Set Up / strong legal system and overall demographic advantage

LEONARDO BARRERA  
Leonardo has type 1 diabetes  
Mexico

# Global experience of accelerating innovation

Martin Lange  
Executive Vice President Development  
Novo Nordisk A/S



# Novo Nordisk at a glance

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.

Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.

We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease.

**Products marketed in**  
**169**  
countries

**1756**  
million INR  
invested in R&D<sup>1</sup>

Supplier of  
nearly  
**50%**  
of the world's  
insulin

**32.8**  
million people use our  
diabetes care products

**Affiliates in**  
**80**  
countries

**R&D centres**  
in China, Denmark,  
India, UK and US

**Strategic production sites** in Denmark,  
Brazil, China, France  
and US

About  
**8500**  
Employees working with  
Research & Development<sup>2</sup>

**Growth disorders**

**Haemophili**

**Diabetes**

**Obesity**

Among the world's  
**5**  
largest pharma companies  
measured by market cap<sup>3</sup>

1. Between 2016 and 2020  
2. Including ~2500 in CMR  
3. Medwatch & Data on file

# Research and Development in Novo Nordisk





CVD: cardiovascular disease; CKD: Chronic Kidney Disease; NASH: non-alcoholic steatohepatitis; RNAi: RNA interference;

1. Between 2016 and 2020

2 In 2021

# Novo Nordisk's innovation model is built on dedicated disease understanding and focused innovation

Focused innovation with 12 new products in less than 10 years



Collaboration with academic and commercial partners




Strong foundation of **basic research** and accumulation of insights



1. Spector J.M, Harrison R.S., Fishman, M.C. Fundamental science behind today's important medicines. *Science Translational Medicine*. 2018; 10:eaaq1787

# Novo Nordisk has an innovative pipeline with novel technologies and multiple therapeutic targets



1: Projects on-hold  
2: Project expected to skip phase 2  
4: Terminated further clinical development activities and investments towards G2 for the lead GSI 1845 molecule  
5: Launched in the US under the brand name Wegovy®

SOMA device photo credit: Felice Frankel, MIT

# Novo Nordisk developed the first oral biologic diabetes treatment

**1<sup>st</sup>** GLP-1 RA in a pill


**15** years of scientific development

**8** years of clinical research



RHONA BAPTISTE  
Rhona has type 2 diabetes  
UK

# By being a sustainable business we add value to society and to our future business





ново нордиск®